YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–b…
Nurix Therapeutics, Inc. Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 0…
Nurix Therapeutics, Inc. Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACs BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX),…
Nurix Therapeutics NRIX continues to make steady progress with bexobrutideg, the company's lead product candidate and primary clinical value driver. Nurix is developing bexobrutideg as an oral, brain-penetrant and highly selective Bruton's…
Nurix Therapeutics, Inc. (NRIX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impac…
Kymera Therapeutics KYMR is leveraging targeted protein degradation, a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The c…
Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The invest…
(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation. Delcath Systems Inc. (DCTH) Delcath Systems is an interventi…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Nurix Therapeutics (NasdaqGM:NRIX) announced a $10 million milestone payment tied to the first in h…
Nurix Therapeutics, Inc. Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approx…
BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating bexobrutideg, a pote…
Nurix Therapeutics, Inc. Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor BRISBANE, Calif., Aug. 04, 2026 (…
Kymera Therapeutics KYMR is leveraging targeted protein degradation (TPD), a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins.…
Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 30.4 billion ($38.6 billion) in the first half of 2026, down 2% year over year due to the significant appreciation of the Swiss franc. Sales were up 6% at constant exchange ra…
(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced the closing of its previously announced global collaboration agreement with Roche Holding AG (RHHBY) to co-develop and co-commercialise Bexo…
Nurix Therapeutics, Inc. BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protei…
Roche RHHBY announced that the FDA has granted Priority Review to the company's supplemental biologics license application (sBLA) seeking label expansion of Gazyva/Gazyvaro (obinutuzumab). The sBLA is seeking approval of the drug for the t…
Shares of WD-40 Company WDFC surged 10.7% after the company reported third-quarter 2026 earnings of $2.33 per share, beating the Zacks Consensus Estimate of $1.58 per share. Delta Air Lines, Inc. DAL shares fell 1.8% after the company repo…
(RTTNews) - Nurix Therapeutics, Inc. (NRIX) reported financial results for the second quarter ended May 31, 2026, reflecting a wider net loss and a decline in revenue. In addition, the company provided operational and pipeline updates. Com…
Nurix Therapeutics, Inc. Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes…
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical d…
The S&P 500 Index ($SPX) (SPY) today is up +0.47%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.55%. September E-mini S&P futures (ESU26) are up +0.47%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.47%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.55%. September E-mini S&P futures (ESU26) are up +0.47%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.27%. September E-mini S&P futures (ESU26) fell -0.35%, a…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.27%. September E-mini S&P futures (ESU26) fell -0.35%, a…
September S&P 500 E-Mini futures (ESU26) are down -0.96%, andSeptember Nasdaq 100 E-Mini futures (NQU26) are down -1.34% this morning as sentiment took a hit after U.S. President Donald Trump declared an end to the ceasefire with Iran, sen…
Roche RHHBY reported positive results from the late-stage Krascendo 1 study evaluating experimental candidate, divarasib, in patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC). Divarasib is an investigational, ne…
Roche RHHBY announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking label expansion of Enspryng (satralizumab) for the treatment of thyroid eye disease (TED). Enspryn…
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best biotech stocks on this list. TheFly reported on June 18 that Baird increased its price target…
Shares of Nurix Therapeutics NRIX have seen a sharp increase over the past month, primarily driven by growing investor optimism about the company's recently announced collaboration with Swiss pharma giant Roche RHHBY. NRIX's Price Performa…
Nurix Therapeutics, Inc. (NRIX) shares soared 16.4% in the last trading session to close at $22.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain o…
Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the 9 Stocks Winning by Double Digits. Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions followi…
Natera Inc. (NASDAQ:NTRA) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 4, Natera and CytoDyn entered a strategic collaboration to utilize ctDNA-guided insights and molecular response analysis for CytoDyn's met…
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 9, Truist analyst Gregory Renza raised Nurix Therapeutics, Inc. (NASDAQ:NRIX)' price target to $32 from $30. The firm maintai…
Wall Street traded higher on Friday as investors focused on the highly anticipated public debut of SpaceX, with enthusiasm surrounding the offering helping support gains across major U.S. equity indexes. The blue-chip Dow Jones Industrial…
TG Therapeutics TGTX shares ended the last trading session 7.5% higher at $46.62. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2% gain over th…